menu search

SAVA / Cassava Sciences: My Bullish Take On Biomarkers And CTAD Data

Cassava Sciences: My Bullish Take On Biomarkers And CTAD Data
Cassava Sciences' stock is highly disputed due to conflicting opinions on the science behind its drug candidate, but outside research supports its apparent drug effect. Biomarkers show strong reductions in patients treated with simufilam, indicating potential efficacy in Alzheimer's disease. The reduction of NfL values over six months is similar to what led to the accelerated approval of Qalsody for ALS. Read More
Posted: Oct 30 2023, 03:30
Author Name: Seeking Alpha
Views: 112112

SAVA News  

1 Big Red Flag to Fear When a Stock Is Down

By The Motley Fool
October 31, 2023

1 Big Red Flag to Fear When a Stock Is Down

Stocks often lose much of their value as a result of controversies. Cassava Sciences is facing a raft of serious allegations from numerous parties. more_horizontal

Cassava Sciences: My Bullish Take On Biomarkers And CTAD Data

By Seeking Alpha
October 30, 2023

Cassava Sciences: My Bullish Take On Biomarkers And CTAD Data

Cassava Sciences' stock is highly disputed due to conflicting opinions on the science behind its drug candidate, but outside research supports its app more_horizontal

SAVA Stock Continues to Plunge on Misconduct Allegations

By InvestorPlace
October 16, 2023

SAVA Stock Continues to Plunge on Misconduct Allegations

Big problems appear to be getting worse for Cassava Sciences (NASDAQ: SAVA ). The clinical-stage biotech company is a former favorite among retail inv more_horizontal

SAVA Stock Alert: Cassava Sciences Addresses Leaked Report

By InvestorPlace
October 13, 2023

SAVA Stock Alert: Cassava Sciences Addresses Leaked Report

Cassava Sciences (NASDAQ: SAVA ) stock was hit hard after the market close yesterday following the publication of a Science article that released the more_horizontal

Cassava Sciences slumps after leaked report claims 'egregious misconduct' over Alzheimer's drug

By Proactive Investors
October 13, 2023

Cassava Sciences slumps after leaked report claims 'egregious misconduct' over Alzheimer's drug

Cassava Sciences Inc has denied data manipulation after a probe into conduct over its Alzheimer's drug research was leaked yesterday, sending its shar more_horizontal

Cassava shares plummet after investigation accuses researcher of ‘egregious misconduct'

By Market Watch
October 13, 2023

Cassava shares plummet after investigation accuses researcher of ‘egregious misconduct'

Shares of biotech company Cassava Sciences Inc. were slammed in extended trading Thursday, after the publication Science reported that an investigatio more_horizontal

Cassava Sciences slumps after leak claims “egregious misconduct”

By Proactive Investors
October 13, 2023

Cassava Sciences slumps after leak claims “egregious misconduct”

Cassava Sciences Inc has denied data manipulation after a probe into conduct over its Alzheimer's drug research was leaked yesterday, sending its shar more_horizontal

Why Shares of Cassava Sciences Soared This Week

By The Motley Fool
October 6, 2023

Why Shares of Cassava Sciences Soared This Week

A rash of insider buying helped buoy the clinical-stage biotech's stock. Cassava said it had completed the enrollment of a phase 3 trial for an Alzhei more_horizontal


Search within

Pages Search Results: